Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes

American Journal of Hypertension

Volumn 20, Issue 7 SUPPL., 2007, Pages

  Zannad, Faiez ^a  

^a INSERM   (France)

Author keywords

diabetes; Hypertension; perindopril indapamide

Indexed keywords

ALBUMIN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; LOSARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; ESSENTIAL HYPERTENSION; HEART AFTERLOAD; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTENSION; MONOTHERAPY; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; TREATMENT OUTCOME;

EID: 34249718869     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.04.014     Document Type: Article

References (27)

1. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
2. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
3. Materson B.J., Reda D.J., Cushman W.C., Henderson W.G., and Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Results of combination anti-hypertensive therapy after failure of each of the components. J Hum Hypertens 9 (1995) 791-796
4. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J.H., McInnes G.T., Mitchell L., Plat F., Schork M.A., Smith B., and Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 (2004) 2049-2051
5. Standards of medical care in diabetes. Diabetes Care 28 Suppl 1 (2005) S4-S36
6. Kasiske B.L., Kalil R.S., Ma J.Z., Liao M., and Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118 (1993) 129-138
7. Chalmers J., Castaigne A., Morgan T., and Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 18 (2000) 327-337
8. Mogensen C.E., Viberti G., Halimi S., Ritz E., Ruilope L., Jermendy G., Widimsky J., Sareli P., Taton J., Rull J., Erdogan G., De Leeuw P.W., Ribeiro A., Sanchez R., Mechmeche R., Nolan J., Sirotiakova J., Hamani A., Scheen A., Hess B., Luger A., and Thomas S.M. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 41 (2003) 1063-1071
9. Dahlof B., Gosse P., Gueret P., Dubourg O., de Simone G., Schmieder R., Karpov Y., Garcia-Puig J., Matos L., De Leeuw P.W., Degaute J.P., and Magometschnigg D. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL Study. J Hypertens 23 (2005) 2063-2070
10. Mourad J.J., Waeber B., Zannad F., Laville M., Duru G., and Andrejak M. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 22 (2004) 2379-2386
11. Mallion J.M., Chamontin B., Asmar R., De Leeuw P.W., O'Brien E., Duprez D., O'Rourke M.F., Rahn K.H., Romero R., Battegay E., Hitzenberger G., and Safar M.E. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON Study. Am J Hypertens 17 (2004) 245-251
12. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
13. Waeber B., and Mourad J.J. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens 19 (2006) 985-986
14. Roux O., Chapellier M., Czernichow S., Nisse-Durgeat S., Safar M.E., and Blacher J. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 15 (2006) 6-13
15. Chamontin B., Lang T., Vaisse B., Nicodeme R., Antoine M.P., Lazorthes M.L., Gallois H., and Poggi L. Regional management of arterial hypertension in France. Report of a survey of general practitioners. (in French). Arch Mal Coeur 94 (2001) 823-827
16. Mourad J., Vaisse B., and Lopez-Sublet M. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life?. The OPTIMAX Study. (Abstract 1792). Eur Heart J 27 Suppl (2006) 298
17. Holzgreve H., Risler T., and Trenkwalder P. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS Study. Curr Med Res Opin 22 (2006) 1849-1858
18. Wolf-Maier K., Cooper R.S., Kramer H., Banegas J.R., Giampaoli S., Joffres M.R., Poulter N., Primatesta P., Stegmayr B., and Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43 (2004) 10-17
19. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 24 Suppl (2006) S19-S27
20. Mourad J.J., Hanon O., Deverre J.R., Camici P.G., Sellier P., Duboc D., and Safar M.E. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 4 (2003) 94-95
21. Asmar R.G., London G.M., O'Rourke M.E., and Safar M.E. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 38 (2001) 922-926
22. de Luca N., Mallion J.M., O'Rourke M.F., O'Brien E., Rahn K.H., Trimarco B., Romero R., De Leeuw P.W., Hitzenberger G., Battegay E., Duprez D., Sever P., and Safar M.E. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 17 (2004) 660-667
23. Dahlof B., Pennert K., and Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 5 (1992) 95-110
24. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 (1996) 1507-1513
25. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., and Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003) 41-46
26. Stratton I.M., Cull C.A., Adler A.I., Matthews D.R., Neil H.A., and Holman R.R. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49 (2006) 1761-1769
27. Chalmers J., Perkovic V., Joshi R., and Patel A. ADVANCE: breaking new ground in Type 2 diabetes. J Hypertens 24 Suppl (2006) S22-S28